Streetbeat News

ALT

Altimmune, Inc.

https://altimmune.com

Industry

Biotechnology

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Open

8.27

Mkt cap

541M

Volume

5.3M

High

8.54

P/E Ratio

-4.67

52-wk high

14.84

Low

7.46

Div yield

N/A

52-wk low

2.38

On Wednesday, 155 companies set new 52-week lows. The largest company by market cap to set a new 52-week low was Estee Lauder Cos (NYSE:EL). The smallest company by market cap to set a new 52-week low was SenesTech (NASDAQ:SNES). Siyata Mobile (NASDAQ:SYTA)'s stock fell the most, as it traded down 7658.62% to reach a new 52-week low. Sutro Biopharma (NASDAQ:STRO) was the biggest winner of the bunch, with shares actually trading up 0.0% after it rebounded from its new 52-week low.

Portfolio Pulse from Benzinga Insights

August 09, 2023 | 4:27 pm

Altimmune (NASDAQ:ALT) is set to release its quarterly earnings report on August 10, 2023. Analysts estimate an earnings per share (EPS) of $-0.46. The company's past performance shows a pattern of beating EPS estimates but experiencing a drop in share price. Altimmune's shares are currently trading at $3.01, down 78.47% over the last 52-week period.

Portfolio Pulse from Benzinga Insights

August 09, 2023 | 3:01 pm

Altimmune has enrolled the first subject in the Phase 2B IMPACT trial evaluating the efficacy and safety of Pemvidutide in subjects with non-alcoholic steatohepatitis. Topline results are expected in Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2023 | 11:51 am

On Wednesday, 59 companies hit new 52-week lows. The largest company by market cap to hit a new low was TC Energy (NYSE:TRP), while the smallest was China SXT Pharmaceuticals (NASDAQ:SXTC). AppHarvest (NASDAQ:APPH)'s stock fell the most, down 19.83%, while XOMA (NASDAQ:XOMA)'s stock bounced back, moving up 0.0% after hitting a new low.

Portfolio Pulse from Benzinga Insights

July 26, 2023 | 4:18 pm

On Tuesday, 56 companies hit new 52-week lows. The largest company by market cap to set a new low was Apellis Pharmaceuticals, while the smallest was 9 Meters Biopharma. Humanigen's stock came under the most pressure, trading down 73.22%. NeuBase Therapeutics saw the biggest bounce back, with shares trading up 0.0% after hitting its new 52-week low.

Portfolio Pulse from Benzinga Insights

July 25, 2023 | 4:33 pm

On Monday, 70 companies hit new 52-week lows. Estee Lauder Cos was the largest firm by market cap to set a new 52-week low, while 9 Meters Biopharma was the smallest. AppHarvest was the biggest loser, trading down 70.3% to reach its 52-week low, while SWK Holdings was the biggest winner, with shares trading up 0.0% after rebounding from its new 52-week low.

Portfolio Pulse from Benzinga Insights

July 24, 2023 | 7:48 pm

On Friday, 54 companies hit new 52-week lows. The largest company in terms of market cap to set a new 52-week low was NovoCure (NASDAQ:NVCR), while the smallest was Ucommune International (NASDAQ:UK). Sigma Additive Solutions (NASDAQ:SASI) saw the largest move, with shares plummeting 27.56%. Greenbrook TMS (NASDAQ:GBNH) shares were the most resilient, moving up 0.0% in response to hitting its 52-week low.

Portfolio Pulse from Benzinga Insights

July 21, 2023 | 5:24 pm

During Tuesday's trading, 46 companies set new 52-week lows. The largest company by market cap to set a new 52-week low was TELUS (NYSE:TU). American Rebel Holdings (NASDAQ:AREB) was the smallest firm on a market cap basis to set a new 52-week low. 9 Meters Biopharma (NASDAQ:NMTR) was the biggest loser, trading down 68.25% to reach its 52-week low. Shuttle Pharmaceuticals (NASDAQ:SHPH) saw the sharpest rebound, as shares ascended 0.0%, reversing after hitting a new 52-week low.

Portfolio Pulse from Benzinga Insights

July 18, 2023 | 5:47 pm

JMP Securities analyst Jonathan Wolleben has reiterated a 'Market Outperform' rating on Altimmune (NASDAQ:ALT) and maintained a $15 price target.

Portfolio Pulse from richadhand@benzinga.com

July 12, 2023 | 12:59 pm

On Thursday, 109 companies set new 52-week lows. The largest company in terms of market cap to set a new 52-week low was Nasdaq (NASDAQ:NDAQ). Biodexa Pharmaceuticals (NASDAQ:BDRX) was the smallest company in terms of market cap to set a new 52-week low. Sarcos Technology (NASDAQ:STRC) shares dropped the most, trading down 417.35% to reach its new 52-week low. Cineverse (NASDAQ:CNVS) shares were the most resilient, as shares rose 0.0%, rebounding from its new 52-week low.

Portfolio Pulse from Benzinga Insights

July 06, 2023 | 4:58 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.